Pharmacological inhibition of the Menin-MLL interaction appears to be selective to the MLL-fused AML/ALL with differentiation induction and anti-proliferation potential; however, this treatment option still awaits clinical evaluation. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.